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The aim of this study was to investigate corneal enzymatic resistance following epithelium off and on
riboﬂavin/UVA cross-linking (CXL). One hundred and fourteen porcine eyes were divided into four non-
irradiated control groups and seven CXL groups. The latter comprised; (i) epithelium-off, 0.1% iso-
osmolar riboﬂavin, 9 mW UVA irradiation for 10 min, (ii) disrupted epithelium, 0.1% hypo-osmolar
riboﬂavin, 9 mW UVA for 10 min, (iii) epithelium-on, 0.25% hypo-osmolar riboﬂavin with 0.01% ben-
zylalkonium chloride (BACS), 9 mW UVA for 10 min, (iv) epithelium-on, 5 min iontophoresis at 0.1 mA
for 5 min with 0.1% riboﬂavin solution, 9 mW UVA for 10 min or (v) 12.5 min, (vi) epithelium-on, pro-
longed iontophoresis protocol of 25 min with 1.0 mA for 5 min and 0.5 mA for 5 min with 0.25% ribo-
ﬂavin with 0.01% BACS, 9 mW UVA for 10 min or (vii) 12.5 min. Enzymatic resistance was assessed by
daily measurement of a corneal button placed in pepsin solution and measurement of corneal button dry
weight after 11 days of digestion. This study revealed that the enzymatic resistance was greater in CXL
corneas than non-irradiated corneas (p < 0.0001). Epithelium-off CXL showed the greatest enzymatic
resistance (p < 0.0001). The prolonged iontophoresis protocol was found to be superior to all other trans-
epithelial protocols (p < 0.0001). A 25% increase in UVA radiance signiﬁcantly increased corneal enzy-
matic resistance (p < 0.0001). In conclusion, although epithelium-on CXL appears to be inferior to
epithelium-off CXL in terms of enzymatic resistance to pepsin digestion, the outcome of epithelium-on
CXL may be signiﬁcantly improved through the use of higher concentrations of riboﬂavin solution, a
longer duration of iontophoresis and an increase in UVA radiance.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Over the past decade, riboﬂavin/UVA corneal cross-linking (CXL)
has become an established treatment to halt the progression of
keratoconus and other corneal ectasias. Riboﬂavin is a hydrophilic
molecule, with a molecular weight of 340 Da, while, the corneal
epithelium is lipophyllic, with a decreasing permeability to mole-
cules over 180 Da (Huang et al., 1989). Therefore in the “gold-
standard” CXL protocol the epithelium is removed from the central
corneal to allow adequate stromal absorption of riboﬂavin prior to
UVA irradiation. Spoerl et al. conﬁrmed this need for epithelial
removal, reporting no changes in corneal biomechanics when CXLVision Sciences, Cardiff Uni-
).
r Ltd. This is an open access articlewas performed with the epithelium intact (Spoerl et al., 1998). On
this basis, the epithelium was removed in the ﬁrst published clin-
ical studies (Caporossi et al., 2006; Gkika et al., 2011; O'Brart et al.,
2011; Richoz et al., 2013; Wittig-Silva et al., 2014; Wollensak et al.,
2003). However, epithelial debridement is associated with a
number of adverse events, including severe ocular pain in the im-
mediate post-operative period, delayed visual rehabilitation and
the risks of scarring, infectious and non-infectious keratitis (Koller
et al., 2009).
As a result of such considerations, a number of trans-epithelial
CXL techniques have been postulated. The ﬁrst epithelium-on CXL
(epi-on-CXL) protocols included the use of multiple topical appli-
cations of tetracaine 1% to disrupt epithelial tight junctions (Boxer
Wachler et al., 2010; Chan et al., 2007) and partial epithelial
debridement in a grid pattern (Rechichi et al., 2013). More recently,
novel formulations of riboﬂavin have been developed to facilitateunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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rations in which trometamol (Tris-hydroxymethyl-aminometane)
and sodium ethylenediaminetetraacetic acid (EDTA) have been
added facilitate stromal absorption when used in conjunction with
superﬁcial/grid pattern epithelial trauma (Alhamad et al., 2012).
Similarly, preparations without dextran but with sodium chloride
0.44% and benzalkonium chloride (BAC) have been shown to
facilitate trans-epithelial riboﬂavin stromal absorption (Kissner
et al., 2010; Raiskup et al., 2012). Clinical studies with such for-
mulations have demonstrated equivocal results with some sug-
gesting similar efﬁcacy to epithelium-off CXL (epi-off-CXL)
(Filippello et al., 2012; Magli et al., 2013), and others showing less
pronounced effects (Buzzonetti and Petrocelli, 2012; Kocak et al.,
2014; Koppen et al., 2012; Leccisotti and Islam, 2010). As ribo-
ﬂavin is negatively charged at physiological pH and soluble in
water, iontophoresis as a means of enhancing trans-epithelial ab-
sorption has also been postulated. In vitro studies of CXL using
iontophoresis-assisted delivery (Ion-CXL) of riboﬂavin 0.1% with a
current of 0.5e1 mA for 5e10 min have been encouraging,
demonstrating enhanced trans-epithelial riboﬂavin absorption and
corneal tissue biomechanics (Cassagne et al., 2016; Lombardo et al.,
2014; Mastropasqua et al., 2014; Touboul et al., 2014; Vinciguerra
et al., 2014a). Early clinical studies have reported cessation of pro-
gression and improvements in keratometric and visual parameters
(Bikbova and Bikbov, 2014; Buzzonetti et al., 2015; Vinciguerra
et al., 2014b).
In addition to the desire to keep the epithelium intact, the
current “gold-standard”, epi-off-CXL protocol, involves a 30 min
application of riboﬂavin followed by a 30 min irradiation with
370 nm UVA light, with an intensity of 3 mW/cm2, necessitating in
excess of one hour treatment time. In an attempt to reduce treat-
ment times, the use of accelerated CXL (A-CXL) procedures using
the same energy dose but higher UVA intensities and shorter
exposure times have been investigated. Published clinical studies of
A-CXL protocols are relatively few. However, those using 7 mW for
15 min or 9 mW for 10 min have reported improvements in cor-
rected distance acuity and a reduction in topographic keratometry
at up to 46 months follow-up with no adverse events associated
with the high ﬂuences used (Cinar et al., 2014; Cummings et al.,
2016; Kanellopoulos, 2012; Kymionis et al., 2014a; Shetty et al.,
2015). More recently, it has also been demonstrated that the efﬁ-
cacy of A-CXL may be further improved by increasing the UVA
exposure time and the overall cumulative dosage (Aldahlawi et al.,
2016; Kymionis et al., 2014b; Sherif, 2014).
Increased resistance of the corneal stroma to enzymatic diges-
tion following standard (Hayes et al., 2013; Spoerl et al., 2004) and
accelerated (Aldahlawi et al., 2015) epi-off-CXL has been demon-
strated by a number of investigators. It is likely that the improved
enzymatic resistance is an important factor in protection against
disease progression, since an increase in proteinase activity and a
reduction in proteinase inhibitor activity has been identiﬁed in
keratoconic corneas (Zhou et al., 1998). In order to investigate the
efﬁcacy of a number of different epi-on-CXL protocols, we
compared the enzymatic resistance of corneal tissue cross-linked
using epi-off-CXL with that of corneas treated with partially
disrupted-epithelium CXL (dis-CXL), existing epi-on-CXL protocols
(involving different riboﬂavin formulations and modes of delivery)
and a prolonged iontophoresis CXL protocol with 0.25% riboﬂavin
(TC-ion-CXL) that we have recently developed. In addition to this
we examined the effect of increasing the cumulative UVA dosage on
the enzymatic resistance of corneas treated with iontophoresis-
assisted epi-on-CXL. Pepsin was selected as the enzyme of choice
for this study in favour of collagenase, as it is a non-speciﬁc
endopeptidase that can break down both collagen and proteogly-
can core proteins, both of which are believed to be sites ofriboﬂavin/UVA induced cross-links (Hayes et al., 2013). Porcine eyes
were used as, unlike human cadaver eyes and rabbit eyes which are
of limited availability in the UK, they were readily available in the
fresh state and in the large numbers required for this study. How-
ever, due to the porcine cornea having a thicker epithelium than the
human cornea, the results presented herein should be regarded as a
conservative assessment of the effectiveness of trans-epithelial
CXL.
2. Materials and methods
2.1. Specimen preparation
A total of one hundred and fourteen fresh porcine cadaver eyes
with clear corneas and intact epithelium were retrieved from a
local European Community licensed abattoir within 6e8 h of death.
Due to the large number of eyes and treatment groups involved, it
was necessary to split the study into two runs. Run 1 examined the
effectiveness of dis-CXL and epi-on-CXL protocols at increasing
corneal enzymatic resistance to digestion with pepsin, whilst run 2
examined the effect on enzymatic resistance of increasing the UVA
dosage by 25% from 5.4 J/cm2 to 6.75 J/cm2 during iontophoretic
epi-on-CXL. In both runs, the effectiveness of the standard epi-off
CXL protocol at increasing enzymatic resistance was also exam-
ined for comparative purposes. The 11 treatment groups are
described below and summarised in Table 1.
Run 1:
Each treatment group consisted of six eyes.
i) Epi-off standard protocol (Group 1: Epi-off-ribo; Group 2:
Epi-off-CXL)
Complete corneal epithelial debridement was performed in
groups 1 and 2 using a single edged razor blade. These eyes then
received 0.1% riboﬂavin eye drops containing 20% dextran T-500
solution (Mediocross D®, Peschke Meditrade, Huenenberg,
Switzerland) every 5 min for 30 min. The central 9 mm region of
corneas in group 2 was then exposed to 365 nm UVA light with a
ﬂuence of CXL 9 mW/cm2 for 10min using a CCL-365 Vario™ cross-
linking system (Peschkmed, Huenenberg, Switzerland). During
irradiation, riboﬂavin was re-applied at 5 min intervals. Group 1
served as a non-irradiated control.
ii) Epi-disrupted protocol (Group 3: Dis-ribo; Group 4: Dis-
CXL)
Partial epithelial disruptionwas performed in groups 3 and 4, by
making 64 full-thickness epithelial punctures with a 25 gauge
needle in an 8  8 grid pattern. The corneas were then soaked in
riboﬂavin 0.1% dextran-free solution (Vitamin B2 Streuli, Uznach,
Switzerland) for 30 min and rinsed with phosphate-buffered saline
(PBS) for 5 min. Group 4 was then irradiated with 9 mW UVA for
10 min with PBS applied at 5 min intervals to keep the corneal
surface moist. Group 3 served as a non-irradiated control.
iii) Epi-on and high riboﬂavin concentration protocol (Group
5: Medio-ribo; Group 6: Medio-CXL)
Groups 5 and 6 received 0.25% riboﬂavin with 1.2% hydrox-
ypropylmethyl cellulose (HPMC) and 0.01% BAC (Mediocross TE®,
Peschketrade, Huenenberg, Switzerland) every 5 min for 30 min.
This was followed by a 5 min rinse with PBS. Group 6 was then
irradiated with 9 mW UVA for 10 min with PBS applied at 5 min
intervals. Group 5 served as a non-irradiated control.
iv) Epi-on, high riboﬂavin concentration and prolonged
iontophoresis (St. Thomas-Cardiff) protocol (Group 7: TC-ion-
ribo; Group 8: TC-ion-CXL)
Groups 7 and 8 received iontophoresis assisted delivery of 0.25%
riboﬂavin with 1.2% HPMC and 0.01% BAC (Mediocross TE®,
Peschketrade, Huenenberg, Switzerland) using a current of 1 mA
for 5 min. The corneas were then soaked with this riboﬂavin
Table 1
Treatment groups.




Epi-off-ribo Off Mediocross D: 0.1% Riboﬂavin,
20% dextran
e 30 min e e e e e
(2) Epithelium-off standard CXL Epi-off-CXL 5.4 J/cm2 Off Mediocross D e 30 min e e e 10 min Mediocross D
(3) Disrupted epithelium non-
irradiated control
Dis-ribo Disrupted Vitamin B2 Streuli: 0.1%
riboﬂavin, saline
e 30 min e e 5 min e e
(4) Disrupted epithelium CXL Dis-CXL 5.4 J/cm2 Disrupted Vitamin B2 Streuli e 30 min e e 5 min 10 min PBS
(5) Epithelium intact non-irradiated
control
Medio-ribo On Mediocross TE: 0.25%
riboﬂavin, 1.2% HPMC, 0.01%
BACS, Pi-water
e 30 min e e 5 min e e
(6) Epithelium intact high riboﬂavin
concentration CXL
Medio-CXL 5.4 J/cm2 On Mediocross TE e 30 min e e 5 min 10 min PBS
(7) Epithelium intact, high riboﬂavin
concentration and prolonged
iontophoresis non-irradiated control
TC-ion-ribo On Mediocross TE 5 min 5 min 5 min 5 min 5 min e e
(8) Epithelium intact, high riboﬂavin
concentration and prolonged
iontophoresis CXL
TC-ion-CXL 5.4 J/cm2 On Mediocross TE 5 min 5 min 5 min 5 min 5 min 10 min PBS
(9) Epithelium intact, high riboﬂavin
concentration, prolonged
iontophoresis and high UVA energy
dose CXL
TC-ion-CXL 6.75 J/cm2 On Mediocross TE 5 min 5 min 5 min 5 min 3 min 12 min 30 s PBS
(10) Epithelium intact, basic
iontophoresis protocol
Ion-CXL 5.4 J/cm2 On Mediocross M: 0.1% riboﬂavin,
1.0% HPMC
5 min e e e 3 min 10 min PBS
(11) Epithelium intact, basic
iontophoresis protocol with high
UVA energy dose
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a power of 0.5 mA/min for 5 min and another 5 min riboﬂavin soak.
The iontophoresis delivery systemwas used to treat ex vivo eyes by
connecting the return electrode to a needle inserted into the vit-
reous chamber; the negative electrode was a steel grid contained in
a corneal well applicator which was adhered to the eye bymeans of
a vacuum well system (Fig. 1). The steel grid (negative electrode)
was completely covered with riboﬂavin and the power generator
set to the desired current and duration. The steel grid remained
covered with riboﬂavin solution for the entire procedure. After
treatment the applicator was removed from the cornea and the
corneas were washed with PBS for 5 min. Group 8 was then irra-
diated with 9 mW UVA for 10min with PBS applied at 5 min in-
tervals. Group 7 served as a non-irradiated control.
Run 2:
Each treatment group consisted of 11 eyes.
i) Epi-off standard protocol (Group 1: Epi-off-ribo; Group 2:
Epi-off-CXL 5.4 J/cm2)
Corneas were treated as described for groups 1 and 2 in run 1.
ii) Epi-on, high riboﬂavin concentration and prolonged
iontophoresis (St. Thomas-Cardiff) protocol (Group 8: TC-ion-
CXL 5.4 J/cm2; Group 9: TC-ion-CXL 6.75 J/cm2)
Groups 8 and 9 received iontophoresis assisted delivery of 0.25%
riboﬂavin with 1.2% HPMC and 0.01% BAC (Mediocross TE®,
Peschketrade, Huenenberg, Switzerland) using a current of 1 mA
for 5min. The corneas were then soaked with this riboﬂavin solu-
tion for 5 min before a further application of iontophoresis with a
power of 0.5 mA/min for 5 min and another 5 min riboﬂavin soak.
Following a 3 min wash with PBS, the corneas in Group 8 were
irradiated with 9 mW UVA for 10 min and those in Group 9 were
irradiated with 9 mW UVA for 12min and 30 s. During irradiation,
PBS was applied to all corneas at 5 min intervals.
iii) Epi-on basic iontophoresis protocol (Group 10: Ion-CXL
5.4 J/cm2; Group 11: Ion-CXL 6.75 J/cm2)
Groups 10 and 11 underwent iontophoresis assisted riboﬂavin
delivery using an isotonic 0.1% riboﬂavin solution (Vitamin B2)
containing 1.0% HPMC dextran-free solution (Mediocross M®,
Peschketrade, Huenenberg, Switzerland) and a 1 mA currentFig. 1. Iontophoresis riboﬂavin delivery sys(Iontophoresis device, Sooft Italia S.p.A, Italy). After treatment the
corneas were washed with PBS for 3 min. Group 10 was then
irradiated with 9 mW UVA for 10min and group 11 was irradiated
with 9 mW UVA for 12 min and 30 s. During irradiation, PBS was
applied to all corneas at 5 min intervals.
2.2. Measurements of corneal thickness
Using a Pachette2™ Ultrasonic Pachymeter (DGH Technology,
Exton, USA), the central corneal thickness was measured in all eyes
prior to treatment and where applicable after removal of the
epithelium, application of riboﬂavin and UVA irradiation.
2.3. Measurements of enzymatic digestion
A corneo-scleral ring was dissected from each eye immediately
following treatment, wrapped tightly in Clingﬁlm™ (to prevent
moisture loss) and refrigerated until all treatments were complete.
An 8 mm corneal button was trephined from the centre of each
cornea using a disposable skin biopsy punch. The corneal buttons
were then immersed into individual plastic tubes, each containing
5 ml of pepsin solution, and incubated in a water bath at a tem-
perature of 23 C. The pepsin solution was made up of 1 g of
>500 U/mg pepsin from porcine gastric mucosa (Sigma-Aldrich,
Dorset, UK) in 10 ml 0.1 M HCL at pH 1.2. The structural integrity of
the most anterior layers of the cornea was assessed by means of
daily measurements of corneal button diameter. The measure-
ments, which were made using an electronic digital caliper,
continued until the specimen could no longer be distinguished
from the surrounding pepsin solution. At this point the tissue was
considered to have undergone complete digestion.
As an additional means of assessing enzymatic resistance, 5
corneal buttons from each of the 6 treatment groups in run 2 were
removed after 11 days in pepsin digest solution and placed in a
60 C oven until a constant dry weight was obtained. The dry
weight of the tissue represents the total mass of undigested tissue
and can therefore be used as an indicator of the effective depth of
cross-linking.tem modiﬁed for use in ex-vivo eyes.
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Measurements of corneal thickness, complete digestion time
and tissue dry weight were statistically analysed using a one-way
analysis of variance (ANOVA) test. Post hoc Bonferroni compari-
sons were used to isolate signiﬁcant interactions. All statistical
analyses were performed with the Statistical Package for the Social
Sciences (IBM SPSS Statistics 20, New York, USA). P < 0.01 was
considered signiﬁcant. Data were presented in the results as
mean ± standard deviation (SD).
3. Results
3.1. Corneal thickness
Fig. 2 shows the average corneal thickness pre-treatment, post-
riboﬂavin application and post-irradiation for each treatment
group in runs 1 and 2. Statistical tests revealed that corneas treated
using the standard, epi-off protocol and an iso-osmolar riboﬂavin
solution (groups 1 and 2) were signiﬁcantly thinner than the cor-
neas in all other groups (p < 0.007).
3.2. Qualitative assessment of riboﬂavin uptake
As shown in Fig. 3, the distinctive yellow colouration of ribo-
ﬂavin was most clearly visible in the epi-off and TC-ion treated
corneas. Although riboﬂavin was also seen in corneas from
other treatment groups, the colour was notably less intense. Pho-
tographs recorded during the irradiation process in run 2 showed aFig. 2. Corneal thickness measurements are shown for each group in run 1 and run 2 before
*In groups 1 and 2 the corneal epithelium (measuring ~90 mm in thickness) was removednon-homogenous distribution of riboﬂavin in Ion-CXL treated
corneas and a more uniform distribution following epi-off CXL and
TC-Ion-CXL.3.3. Pepsin digestion of corneal buttons
Table 2 shows the number of days required for complete tissue
digestion to occur in each irradiated and non-irradiated treatment
group. Although the digestion times of equivalent non-irradiated
(group 1) and cross-linked treatment groups (group 2) were seen
to vary slightly between runs 1 and 2, possibly as a result of dif-
ferences in the breed and age of the pig eyes, the overall trends
were consistent between the two runs. For this reason the data
from each run was normalized against the total digestion time of
the standard epi-off CXL group to facilitate comparison between
the two runs (Figs. 4 and 5).
Figs. 4 and 5 show cumulative measurements of corneal disk
diameter for each irradiated and non-irradiated treatment group
throughout the digestion process. In both runs 1 and 2, the cross-
linked groups showed a signiﬁcantly greater resistance to enzy-
matic digestion than the non-irradiated groups (p < 0.0001). In run
1, complete digestion of all non-irradiated corneas had occurred by
day 13 (Table 2). At the same time point (normalized digestion time
of 0.33), the mean diameter of the epi-off-CXL, dis-CXL, medio-CXL
and TC-ion-CXL groups had only decreased by 39%, 62%, 74%, and
40% respectively (Fig. 4). No signiﬁcant difference was found be-
tween the non-irradiated groups in terms of either the average
corneal button diameter at any time point in the digestion process
or in the time required for complete digestion to occur (Fig. 4).treatment, after riboﬂavin application and where applicable, following UVA irradiation.
as part of the riboﬂavin application process.
Table 2
Time taken for the complete tissue digestion to occur.
Groups Time taken for complete digestion (in days)
Minimum Maximum Average (±SD)
RUN 1
(1) Epi-off-ribo 11 12 11.5 ± 0.55
(2) Epi-off-CXL 5.4 J/cm2 39 40 39.5 ± 0.55
(3) Dis-ribo 11 13 11.8 ± 0.75
(4) Dis-CXL 5.4 J/cm2 15 16 15.6 ± 0.52
(5) Medio-ribo 11 12 11.6 ± 0.51
(6) Medio-CXL 5.4 J/cm2 14 15 14.6 ± 0.52
(7) TC-ion-ribo 11 12 11.3 ± 0.52
(8) TC-ion-CXL 5.4 J/cm2 32 33 32.2 ± 0.41
RUN 2
(1) Epi-off-ribo 9 10 9.5 ± 0.55
(2) Epi-off-CXL 5.4 J/cm2 43 44 43.5 ± 0.55
(8) TC-ion-CXL 5.4 J/cm2 34 35 34.3 ± 0.52
(9) TC-ion-CXL 6.75 J/cm2 41 42 41.7 ± 0.52
(10) Ion-CXL 5.4 J/cm2 27 28 27.3 ± 0.52
(11) Ion-CXL 6.75 J/cm2 34 35 34.5 ± 0.55
Fig. 3. Corneal buttons from each group in run 1 and 2 are shown immediately post-treatment. The characteristic yellow colour of riboﬂavin can be seen most clearly in the
epithelium-removed, riboﬂavin treated corneas (epi-off) and in the corneas that received riboﬂavin via the St Thomas's/Cardiff modiﬁed iontophoresis protocol (TC-Ion). Photo-
graphs recorded during the irradiation process show a non-homogenous distribution of riboﬂavin in corneas treated with the basic iontophoresis protocol (Ion-CXL).
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linked groups in term of the time taken for complete digestion to
occur (Fig. 4). The conventionally treated, epi-off-CXL corneas
(group 2) took signiﬁcantly longer to digest than all other cross-
linked corneas (p < 0.0001). Although less resistant to enzyme
digestion than the epi-off-CXL corneas, the TC-ion-CXL treated
corneas (group 8) took signiﬁcantly longer to digest than corneas
treated with other disrupted epithelium (dis-CXL) or epi-on-CXL
protocols (p < 0.0001).
In run 2, the non-irradiated corneas were completely digested
by day 10 (Table 2). At this same time point, which corresponds to a
normalized digestion time of 0.25, the mean diameter of corneas in
the epi-off-CXL 5.4 J/cm2, TC-ion-CXL 5.4 J/cm2, TC-ion-CXL 6.75 J/
cm2, Ion-CXL 5.4 J/cm2 and Ion-CXL 6.75 J/cm2 treatment groups
had reduced by 21.4%, 16.2%, 13.4%, 26.7% and 19.4% respectively
(Fig. 5). Signiﬁcant differences in themean disk diameter of the CXL
treatment groups were only apparent after 24 days of digestion
(corresponding to a normalized digestion time of 0.6 in Fig. 5). The
epi-off-CXL group (group 2) took longer to undergo complete
digestion than all other cross-linked groups (p < 0.0001) butcorneas treated with the prolonged, high riboﬂavin concentration,
iontophoresis protocol (TC-ion-CXL) were found to persist in the
pepsin digest solution for signiﬁcantly longer than those treated
with the basic Ion-CXL protocol (Fig. 5). In both the Ion-CXL and TC-
ion-CXL treatment groups, an increase in UVA radiance from 5.4 J/
cm2 to 6.75 J/cm2 resulted in a signiﬁcant increase in the time
required for complete digestion to occur (P < 0.0001).
3.4. Undigested tissue mass
In run 2, only the cross-linked corneas remained after 11 days in
pepsin digest solution (Fig. 6). At this time point, the average
stromal dry weight of the epi-off-CXL 5.4 J/cm2 treated corneas
(group 2) was signiﬁcantly higher than that of all other treatment
groups (groups 8,10,11, P < 0.0001; group 9, P < 0.001). The stromal
dry weight did not differ signiﬁcantly between the Ion-CXL 5.4 J/
cm2 and Ion-CXL 6.75 J/cm2 treatment groups (p ¼ 0.32) or be-
tween the TC-ion-CXL 5.4 J/cm2 and TC-ion-CXL 6.75 J/cm2 groups
(p ¼ 0.038). However, corneas treated with the TC-Ion-CXL 6.75 J/
cm2 protocol had a higher stromal dry weight than corneas treated
with basic ion-CXL 5.4 J/cm2 protocol (p < 0.003).
4. Discussion
Attaining adequate stromal riboﬂavin concentration is essential
for CXL. Riboﬂavin acts as a photo-sensitizer for the production of
oxygen free radicals, which drive the CXL process (McCall et al.,
2010) and as a result insufﬁcient stromal absorption may result in
treatment failure (Wollensak et al., 2003; Wollensak and Iomdina,
2009). As riboﬂavin is a hydrophilic molecule which cannot pene-
trate epithelial cell membranes and tight junctions, the ﬁrst ribo-
ﬂavin/UVA CXL protocols required complete central corneal
epithelial debridement prior to riboﬂavin application (Spoerl et al.,
1998;Wollensak et al., 2003). Although epi-off-CXL is considered to
be the gold standard procedure, with multiple prospective and
randomized controlled studies demonstrating its efﬁcacy in terms
of cessation of keratoconus progression and improvements in
keratometric and visual parameters (Caporossi et al., 2006; Gkika
et al., 2011; O'Brart et al., 2011; Richoz et al., 2013; Wittig-Silva
et al., 2014; Wollensak et al., 2003), new methods of epi-on-CXL
Fig. 4. The summed diameter of all corneal disks within each treatment group (n ¼ 6) are shown for run 1 as a function of time in pepsin digest solution. The digestion time for each
treatment group has been normalized against the total digestion time of the standard epi-off CXL group.
Fig. 5. The summed diameter of all corneal disks within each treatment group (n ¼ 6) are shown for run 2 as a function of time in pepsin digest solution. The digestion time for each
treatment group has been normalized against the total digestion time of the standard epi-off CXL group.
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ment, thereby alleviating post-operative pain and potential risks of
infection (Koller et al., 2009). In addition, to reduce the longtreatment times associated with epi-off-CXL with 3mw/cm2 UVA
irradiation, the use of A-CXL protocols using the same energy dose
but higher UVA intensities and shorter exposure times have been
Fig. 6. Corneal button dry weight after 11 days of digestion. Error bars show standard deviation.
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protocols, multiple methodologies, including extensiometry
(Cassagne et al., 2016; Kissner et al., 2010; Vinciguerra et al., 2014a;
Wollensak and Iomdina, 2009), shear wave elastography (Touboul
et al., 2014), Brillouin microscopy (Scarcelli et al., 2013) and
Scheimpﬂug air pulse tonometry (Mastropasqua et al., 2014) have
been employed. However each of these methodologies have their
inherent inaccuracies and as yet there is no agreed best practice for
assessing biomechanical changes following CXL.
Although the precise aetiology of keratoconus is unknown
(Davidson et al., 2014), an increased activity of protease enzymes
and reduced activity of protease inhibitors has been identiﬁed
(Spoerl et al., 2004), with the resultant increase in stromal protein
digestion liable to be a factor in corneal thinning and secondary
biomechanical instability (Andreassen et al., 1980). Spoerl et al.
(2004) reported increased resistance of stromal tissue to enzy-
matic digestion following epi-off CXL with a dose response related
to the intensity of UVA irradiance. This increased resistance to
protease digestion following CXL has been replicated by others
(Hayes et al., 2013; Aldahlawi et al., 2016) and is thought to be an
important factor in preventing disease progression. In this studywe
utilized enzymatic resistance to pepsin digestion to evaluate the
effects of epi-off-CXL, dis-CXL and epi-on-CXL. Although minor
differences in the rate of enzymatic digestion were seen between
similarly treated corneas in runs 1 and 2, possibly due to variations
in the age and breed of the pig eyes in different batches of abattoir
tissue, each run showed an increased resistance in all of the cross-
linked groups compared to their non-irradiated controls. However,
in accordance with the ﬁndings of Wollensak and Iomdina (2009),
which reported corneal stiffness after epi-on-CXL to be only one
ﬁfth of that seen after epi-off-CXL (indicating a reduced cross-
linking effect), we found enzymatic resistance to be signiﬁcantly
greater with epi-off-CXL than with dis-CXL or epi-on-CXL. Whilst
dis-CXL showed a greater resistance to digestion than the non-
irradiated controls, it was not as effective as the other epi-on-CXLprotocols tested, possibly due to the non-homogeneous uptake of
riboﬂavin that we have documented previously (Alhamad et al.,
2012). Such observations are supported by a recently published,
randomized controlled study which showed better corneal ﬂat-
tening with epi-off-CXL than dis-CXL, although interestingly, dis-
CXL resulted in better improvement of corrected distance visual
acuity at 6 months (Razmjoo et al., 2014).
In this study we showed that corneas cross-linked using
Mediocross TE® (Medio-CXL protocol) showed a greater resistance
to enzymatic digestion than non-irradiated controls and dis-CXL
treated corneas. However, the enhanced enzymatic resistance
achieved with Medio-CXL was found to be inferior to that of the
epi-off and ion-CXL protocols. Mediocross TE® is a hypo-osmolar
riboﬂavin solution that contains 0.01% BAC, a cationic surfactant
that can disrupt epithelial tight junctions to increase corneal
permeability to riboﬂavin (Kissner et al., 2010; Raiskup et al., 2012).
Laboratory studies have shown that preparations with sodium
chloride and BAC can facilitate riboﬂavin transfer through an intact
epithelium albeit in a reduced concentration compared to the epi-
off-CXL (Touboul et al., 2014), and with signiﬁcant associated su-
perﬁcial epithelial damage (Uematsu et al., 2007). Published clinical
studies using enhanced riboﬂavin solutions with epithelial pene-
tration enhancers are limited and have produced equivocal results.
Some have reported similar efﬁcacy to epi-off-CXL (Filippello et al.,
2012; Magli et al., 2013), while others have demonstrated less
pronounced effects with high rates of treatment failure (Buzzonetti
and Petrocelli, 2012; Kocak et al., 2014; Koppen et al., 2012;
Leccisotti and Islam, 2010). There are currently only three pub-
lished randomized, controlled trials comparing epi-off and epi-on-
CXL. Two of the studies, with follow-up times of up to 12 months,
reported similar outcomes (Nawaz et al., 2015; Rossi et al., 2015).
However, the third study, showed epi-on-CXL to be safe but
demonstrated continued progression of keratoconus in 23% of cases
at 12 month follow-up (Soeters et al., 2015). The latter result is
consistent with the less pronounced biomechanical changes
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Iomdina, 2009).
As riboﬂavin is negatively charged at physiological pH and sol-
uble in water, the use of iontophoresis has been postulated to
enhance trans-epithelial absorption. Commercially recommended
protocols for iontophoresis utilize 0.1% riboﬂavin solution and
electrical currents of 0.5e1 mA for 5e10 min. Treatment of rabbit
corneas by this means has been shown to reduce the stromal
riboﬂavin uptake achieved with epi-off-CXL by two thirds, but to
produce a similar improvement in corneal biomechanics (Cassagne
et al., 2016). Studies on rabbit and human cadaver corneas have
demonstrated similar ﬁndings, with better riboﬂavin penetration
and increased elastometry measurements obtained with Ion-CXL
than with epi-on-CXL (using Ricrolin TE) but less than epi-off-CXL
(Vinciguerra et al., 2014a). In a human donor eye model, Mas-
tropasqua et al. demonstrated a corneal stiffening effect following
Ion-CXL (Mastropasqua et al., 2014), with Lombardo et al. (2014)
reporting an almost comparable effect on corneal stiffness to that
with epi-off-CXL. These ﬁndings have been conﬁrmed by super-
sonic shear wave elastography (Touboul et al., 2014). Furthermore,
initial clinical studies in prospective case series have reported
cessation of keratoconus progression with up to 15 month follow-
up and some limited improvements in keratometric and visual
parameters (Bikbova and Bikbov, 2014; Buzzonetti et al., 2015;
Vinciguerra et al., 2014b). However, the relative efﬁcacy of this
technique compared to epi-off-CXL remains to be determined
especially over longer term follow-up.
Using spectrophotometry (Hayes et al., 2015) and two-photon
ﬂuorescence microscopy (Gore et al., 2014), we have found that
stromal riboﬂavin absorption in epithelium-intact corneas can be
improved by increasing riboﬂavin concentration, epithelial contact
time and iontophoresis dosage. Based on this work, we have
modiﬁed the basic Sooft italia Ion-CXL protocol (Sooft italia S.p.A,
Motegiorgio, Italy) and developed the St Thomas's/Cardiff modiﬁed
iontophoresis protocol (TC-ion-CXL) which uses Mediocross TE® as
the iontophoretic solution instead of Ricrolinþ®, as the riboﬂavin
concentration of the former is higher (0.25%) and the use of the
cationic surfactant BAC has been shown with percutaneous treat-
ment to have synergistic effect with iontophoresis on the transport
of anions (Fang et al., 1998). In addition to using this formulation,
the modiﬁed protocol employed a riboﬂavin-epithelial contact
period of 5 min after iontophoresis to allow time for the sub-
epithelial iontophoretically delivered riboﬂavin to diffuse homo-
geneously into the stroma, as well as an increased dosage of
iontophoresis with a second treatment 5 min after the ﬁrst. Results
from the present study demonstrated that both the basic Ion-CXL
and modiﬁed TC-ion-CXL protocols resulted in a greater resis-
tance to enzymatic digestion than all other dis-CXL and trans-
epithelial CXL protocols tested. Furthermore, as we have demon-
strated previously for epi-off CXL treated corneas (Aldahlawi et al.,
2016), we have now shown that the enzymatic resistance of Ion-
CXL and TC-ion-CXL treated corneas can also be enhanced by
increasing the cumulative energy dose and allowing additional
type I photochemical cross-linking to occur. The improvement in
enzymatic resistance was evidenced by the Ion-CXL and TC-ion-
CXL corneas treated with a total energy dose of 6.75 J/cm2 per-
sisting for longer in enzyme digest solution than those that
received a lower energy dose of 5.4 J/cm2. The absence of any dif-
ference in their dry weights after 11 days of digestion is likely
explained by the fact that at this stage of the digestion process, the
rate of digestion was similar for both the high and low energy
treatment groups and signiﬁcant differences in average corneal
disk diameter were not observed until day 24.
The enzymatic resistance achieved with the TC-ion-CXL 6.75 J/
cm2 protocol was closest to that of the standard epi-off-CXL 5.4 J/cm2 protocol, suggesting that this technique may be the best trans-
epithelial alternative for epi-off-CXL. Its slightly lower efﬁcacy
compared to epi-off-CXL, demonstrated by measurements of
corneal disk diameter and tissue dry weight, may be due to a
reduced riboﬂavin stromal absorption or due to other factors. These
might include absorption of UVA by riboﬂavin within the epithe-
lium, resulting in shielding of the underlying stroma and a reduced
UVA dosage to the stroma, although this is unlikely as a 3 min PBS
wash of the ocular surface was performed before UVA exposure.
Another possible cause of the reduced efﬁcacy might be the oxygen
consumption by the epithelium itself (Harvitt and Bonanno, 1998),
which could reduce the amount of oxygen available to the stroma to
drive the CXL process (McCall et al., 2010). Such problems may be
overcome by additional manipulation of the UVA dosage, in terms
of its intensity and duration and/or by increasing oxygen avail-
ability and require further investigation. One further explanation
may be the limitation of our porcine model. As the porcine cornea
has a much thicker corneal epithelium than the human cornea
(90 mm and 50 mm respectively), the results of the current study
should be regarded as a conservative assessment of the effective-
ness of trans-epithelial CXL. Unfortunately, human donor corneas
are unsuitable for examining the effects of CXL on enzymatic
resistance due to the fact that donors are typically over 60 years old,
and the naturally occurring cross-links which increase with age,
may mask the effects of the CXL treatment under investigation.
However, it would be interesting to repeat our methodology in the
rabbit model which has a thinner epithelium (40 mm) and is closer
in thickness to that of the human cornea. Such a study would
complement our current ﬁndings by providing a more liberal es-
timate of the effectiveness of trans-epithelial cross-linking.
This study, which shows our St Thomas'/Cardiff modiﬁed
iontophoresis protocol (TC-ion-CXL) to bemore effective than other
trans-epithelial CXL protocols at increasing the enzymatic resis-
tance of the cornea supports the concept that iontophoresis-
assisted CXL may, with modiﬁcations in terms of riboﬂavin con-
centration, duration of iontophoretic treatment, riboﬂavin soak-
time and UVA energy dose, be an effective technique to prevent
the progression of keratoconus and avoid the postoperative pain
associated with epithelial debridement. Such a technique is
envisaged to be especially useful for eyes that are not eligible for
treatment with epi-off-CXL due to minimum corneal thickness
values less than 400 mm. Further laboratory studies to optimize this
protocol and randomized, prospective clinical studies to compare
its efﬁcacy with epi-off CXL are indicated and are currently being
undertaken (O'Brart D, personal communication, International
Standard Randomized Controlled Trials Number: 04451470).
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